Leuven.Inc

PharmaAbs: Launching Event, October 1, 2008


Auditorium BMW 6, Gasthuisberg, O&N II, Herestraat 49, Leuven

PharmAbs is a research center that focuses on production, development and characterization of antibody-based molecules. It has been founded by K.U.Leuven R&D and five groups of the K.U.Leuven which clustered their complementary expertise in a validated platform that can deliver tailor-made monoclonal, full human or humanized antibodies, antibody fragments or antibody-based molecules (see www.pharmabs.org).

PharmAbs has created a state-of-the-art antibody technology platform open for co-development projects with K.U.Leuven research groups, as well as for contract research collaborations with industrial partners.

The central objectives of PharmAbs are
- to fill the current need of academic research groups for customized antibodies and antibody-based tests
- to create a significant added value for academic biomedical research projects and to bring these projects to the level of optimal commercial value
- to facilitate biotechnology development into the maze of the critical path of antibody-based therapeutics or diagnostics development

Program:
18.00h: Welcome address
18.10h: 'University need for a technology transfer organisation' - Prof. Dr. H. Deckmyn
18.20h: 'PharmAbs: mission and strategy' - Dr. N. Geukens
19.00h: Reception

Attendance is free of charge, but registration is required. To register, please complete the attached registration form and return before September 24 to nick.geukens@kuleuven-kortrijk.be.

Launching Event, October 1, 2008 - Registration form

( ) Yes, I would like to sign up for the PharmAbs Launching Event, October 1, 2008.

The following colleagues will join me:
1.
2.

( ) Yes, I (we) would like to join for the free reception.

( ) Unfortunately I will not be able to join this event, but I am interested in PharmAbs and I want to be kept informed about upcoming PharmAbs events.

Company/university:
Name:
Position:
Telephone number:
E-mail:

Subscribe to our newsletter

Stay tuned and get our news in your inbox: subscribe here.

Keep me informed
Follow us